Boston Scientific Corporation (BSX) managed to stay afloat and traded higher with an addition of 0.06 point or 0.25% at $24.12. The money flow data is a negative $(-1.41) million with $0.48 million in upticks and $1.89 million in downticks. The intraday up/down ratio came in at 0.25. The shares has seen 1.05% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $0 million and the combined worth of the downticks was $1.59, Million, leading to the up/down ratio of 0. The block trade saw a net money flow of $(-1.59) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Boston Scientific Corporation rose by 1.61% in the last five trading days and 10.77% for the last 4 weeks. Boston Scientific Corporation is up 8.91% in the last 3-month period. Year-to-Date the stock performance stands at 10.77%. Boston Scientific Corporation (NYSE:BSX) witnessed a decline in the market cap on Wednesday as its shares dropped 0.42% or 0.1 points. After the session commenced at $24, the stock reached the higher end at $24.18 while it hit a low of $23.765. With the volume soaring to 13,129,606 shares, the last trade was called at $23.96. The company has a 52-week high of $24.79. The company has a market cap of $32,626 million and there are 1,361,677,100 shares in outstanding. The 52-week low of the share price is $15.67.
Company has reported several Insider transactions to the SEC, on Jan 10, 2017, David A Pierce (SVP and President, Endoscopy) sold 10,232 shares at 22.24 per share price.On Jan 10, 2017, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 6,195 shares at 22.24 per share price.On Aug 15, 2016, John Bradley Sorenson (SVP, Manuf & Sup Chn) sold 2,500 shares at 23.90 per share price.
Boston Scientific Corporation Last issued its quarterly earnings results on Oct 26, 2016. The company reported $0.27 EPS for the quarter. Analyst had a consensus estimate of $0.27. The company had revenue of $2105.00 million for the quarter, compared to analysts expectations of $2068.25 million. The companys revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.24 EPS.
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The companys products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.